Details of the Drug Combination

General Information of Drug Combination (ID: DCVMZGP)

Drug Combination Name
Bedaquiline Moxifloxacin
Indication
Disease Entry Status REF
Pulmonary Tuberculosis Phase 2 [1]
Component Drugs Bedaquiline   DM3906J Moxifloxacin   DMU8V4S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Bedaquiline
Disease Entry ICD 11 Status REF
Drug-resistant tuberculosis N.A. Approved [2]
Multi-drug resistant tuberculosis MG52.00 Approved [3]
Pulmonary tuberculosis 1B10.Z Approved [2]
Bedaquiline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium Proton pump (MycB Prop) TT19K0L A0A1Q4HQH4_9MYCO Modulator [6]
------------------------------------------------------------------------------------
Bedaquiline Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Moxifloxacin
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [5]
Peritonitis N.A. Approved [5]
Pneumonic plague N.A. Approved [5]
Septicemic plague N.A. Approved [5]
Staphylococcal pneumonia N.A. Approved [5]
Staphylococcus aureus infection N.A. Approved [5]
Streptococcal pneumonia N.A. Approved [5]
Tuberculosis 1B10-1B14 Approved [5]
Pneumonia caused by chlamydia N.A. Investigative [5]
Pneumonia due to Klebsiella pneumoniae CA40.03 Investigative [5]
Moxifloxacin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [8]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Tuberculosis, Pulmonary DCDV78F N. A. Phase 2 [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT06114628) Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
2 Bedaquiline FDA Label
3 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
4 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
5 Moxifloxacin FDA Label
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 ClinicalTrials.gov (NCT05926466) BTZ-043 Dose Evaluation in Combination and Selection